Based in Israel, BIOMx is a clinical-stage microbiome company that focuses on developing innovative microbiome therapeutics. Their mission is to create novel treatments for diseases associated with microbiome imbalances. By leveraging cutting-edge research from scientific collaborators at renowned institutions like the Weizmann Institute of Science and the Massachusetts Institute of Technology, BIOMx utilizes microbiome modulation technologies to develop both natural and engineered phage cocktails. These cocktails are designed to target and eliminate harmful bacteria, not only in chronic diseases like inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis but also in conditions affecting the appearance of the skin, such as atopic dermatitis. BIOMx discovers and validates proprietary bacterial targets, tailoring phage compositions to effectively combat specific bacteria.